C12N 2501/53
Cd2
C12N2501/53 (Cd2) appears on 22 US grants and 56 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 56
- Assignees
- 36
- Inventors
- 115
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 0 | 3 |
| 2004 | 1 | 2 |
| 2005 | 2 | 2 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 3 |
| 2019 | 1 | 2 |
| 2020 | 0 | 2 |
| 2021 | 4 | 6 |
| 2022 | 0 | 9 |
| 2023 | 2 | 2 |
| 2024 | 2 | 12 |
| 2025 | 5 | 5 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Systems and apparatuses for cellular therapeutics manufacture10 Feb 2026US 12,545,878 B2Bruker Cellular Analysis, Inc.
- Composition for culturing peripheral blood monocyte-derived regulatory t cell and regulatory T cell culturing method using same18 Nov 2025US 12,473,534 B2Immunisbio Co., Ltd.
- Method for enhancing production of genetically engineered autologous T cells5 Aug 2025US 12,378,521 B2Amgen Inc.
- Composition for culturing natural killer cells and method for preparing natural killer cells by using same5 Aug 2025US 12,378,526 B2Gi Cell, Inc.
- Soluble antibody complexes for T cell or NK cell activation and expansion8 Jul 2025US 12,351,825 B2Stemcell Technologies Canada Inc.
- Metabolically enhanced vd1 t cells and uses thereof8 Oct 2026US 2026/0308518 A1
- Systems and apparatuses for cellular therapeutics manufacture27 Aug 2026US 2026/0250617 A1Bruker Spatial Biology, Inc.
- Method for enhancing production of genetically engineered autologous t cells20 Nov 2025US 2025/0354116 A1Amgen Inc.
- Soluble Antibody Complexes For T Cell Activation and Expansion9 Oct 2025US 2025/0313805 A1Stemcell Technologies Canada Inc.
- Cellular microcompartments comprising lymphocytes forming a 3d grouped culture and having a low granzyme b content31 Jul 2025US 2025/0243460 A1Treefrog Therapeutics
Most cited
By later US patents
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005
- Purification and uses of dendritic cells and monocytes24US 7,273,753 B2Center of Blood Research · 2007
- Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof15US 10,273,280 B2iCell Gene Therapeutics Inc. · 2019